44 research outputs found
ΠΠ²ΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΡ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ° ΠΎΠ±ΠΎΠ³Π°ΡΠ΅Π½ΠΈΡ ΠΆΠ΅Π»Π΅Π·Π½ΡΡ ΡΡΠ΄ ΠΏΠΎ ΡΠΈΠ³Π½Π°Π»Π°ΠΌ ΠΌΠ°Π³Π½ΠΈΡΠ½ΠΎΠΉ ΠΈΠ½Π΄ΡΠΊΡΠΈΠΈ ΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΡΠ°
Recombinant antibodies can be used to diagnose, treat and prevent disease by exploiting their specific antigen-binding activities. A large number of drugs currently in development are recombinant antibodies and most of these are produced in cultured rodent cells. Although such cells produce authentic functional products, they are expensive, difficult to scale-up and may contain human pathogens. Plants represent a cost-effective, convenient and safe alternative production system and are slowly gaining acceptance. Five plant-derived therapeutic recombinant antibodies (plantibodies) are undergoing clinical evaluation, three of which can be used as prophylactics
Π‘ΠΎΠ·Π΄Π°Π½ΠΈΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ½ΡΡ ΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΠΈΠΎΠ½Π½ΡΡ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² Ρ Π½Π΅ΠΏΡΠ΅ΡΡΠ²Π½ΡΠΌ Π°ΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π°ΡΠ°ΠΌΠΈΠ΄Π½ΡΠΌ Π²ΠΎΠ»ΠΎΠΊΠ½ΠΎΠΌ Π΄Π»Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² Π°Π΄Π΄ΠΈΡΠΈΠ²Π½ΡΡ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΡΡ
Π Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° Π½Π° ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ½ΠΎΠΉ ΠΎΡΠ½ΠΎΠ²Π΅ Ρ Π½Π΅ΠΏΡΠ΅ΡΡΠ²Π½ΡΠΌ Π°ΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π°ΡΠ°ΠΌΠΈΠ΄Π½ΠΎΠ³ΠΎ Π²ΠΎΠ»ΠΎΠΊΠ½Π° Π΄Π»Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² Π°Π΄Π΄ΠΈΡΠΈΠ²Π½ΡΡ
ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΡ
. ΠΠΏΠΈΡΠ°Π½Ρ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠ° ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠΈ Π°ΡΠ°ΠΌΠΈΠ΄Π½ΠΎΠ³ΠΎ Π²ΠΎΠ»ΠΎΠΊΠ½Π°. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠΈ Π½Π° Π°Π΄Π³Π΅Π·ΠΈΠΎΠ½Π½ΡΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° ΠΏΠΎΠ»ΡΡΠ°Π΅ΠΌΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ·ΠΈΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°
ΠΠ½ΡΠΎΡΠΌΠ°ΡΡΠΉΠ½Π΅ Π·Π°ΠΊΠΎΠ½ΠΎΠ΄Π°Π²ΡΡΠ²ΠΎ. ΠΡΠ½ΠΎΠ²Π½Ρ Π½ΠΎΡΠΌΠ°ΡΠΈΠ²Π½Ρ Π°ΠΊΡΠΈ
ΠΠ°Π²Π΅Π΄Π΅Π½ΠΎ ΠΎΡΠ½ΠΎΠ²Π½Ρ Π½ΠΎΡΠΌΠ°ΡΠΈΠ²Π½Ρ Π°ΠΊΡΠΈ Π· ΡΠ΅Π³ΡΠ»ΡΠ²Π°Π½Π½Ρ ΡΠ½ΡΠΎΡΠΌΠ°ΡΡΠΉΠ½ΠΈΡ
Π²ΡΠ΄Π½ΠΎΡΠΈΠ½, Π·ΠΎΠΊΡΠ΅ΠΌΠ°, Ρ ΡΡΠ΅ΡΡ ΡΠ½ΡΠΎΡΠΌΠ°ΡΡΡ, ΡΠ½ΡΠΎΡΠΌΠ°ΡΡΠΉΠ½ΠΈΡ
Π°Π³Π΅Π½ΡΡΡΠ², ΡΠ΅Π»Π΅ΠΊΠΎΠΌΡΠ½ΡΠΊΠ°ΡΡΡ,
ΡΠ°Π΄ΡΠΎΡΠ°ΡΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠ΅ΡΡΡΡΡ Π£ΠΊΡΠ°ΡΠ½ΠΈ, ΡΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠ·Π°ΡΡΡ, ΡΠ΅Π»Π΅Π±Π°ΡΠ΅Π½Π½Ρ ΡΠΎΡΠΎ.
Π ΠΎΠ·ΡΠ°Ρ
ΠΎΠ²Π°Π½ΠΎ Π½Π° ΡΡΡΠ΄Π΅Π½ΡΡΠ², ΡΠΊΡ Π·Π΄ΠΎΠ±ΡΠ²Π°ΡΡΡ Π²ΠΈΡΡ ΠΎΡΠ²ΡΡΡ Π² Π³Π°Π»ΡΠ·ΡΡ
Π·Π½Π°Π½Ρ "ΠΡΠ°Π²ΠΎ", "ΠΠ½ΡΠΎΡΠΌΠ°ΡΡΠΉΠ½Π° Π±Π΅Π·ΠΏΠ΅ΠΊΠ°", "ΠΠΎΠΌΠΏ'ΡΡΠ΅ΡΠ½Ρ Π½Π°ΡΠΊΠΈ", "Π’Π΅Π»Π΅ΠΊΠΎΠΌΡΠ½ΡΠΊΠ°ΡΡΡ"
Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΠΌΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠ° Π³ΠΈΠ΄ΡΠΎΠΎΡΠΈΡΡΠΊΠΈ Π²Π°ΠΊΡΡΠΌΠ½ΠΎΠ³ΠΎ Π΄ΠΈΡΡΠΈΠ»Π»ΡΡΠ°
Plants are now gaining widespread acceptance as a general platform for the large-scale production of recombinant proteins. The first plant-derived recombinant pharmaceutical proteins are reaching the final stages of clinical evaluation, and many more are in the development pipeline. Over the past two years, there have been some notable technological advances in this flourishing area of applied biotechnology, as shown by the continuing commercial development of novel plant-based expression platforms. There has also been significant success in tackling some of the limitations of plant bioreactors, such as low yields and inconsistent product quality, that have limited the approval of plant-derived pharmaceuticals
Formation classification based on the well logs data with the use of machine learning
Plant-derived pharmaceuticals are poised to become the next major commercial development in biotechnology. The advantages they offer in terms of production scale and economy, product safety, ease of storage and distribution cannot be matched by any current commercial system; they also provide the most promising opportunity to supply low-cost drugs and vaccines to the developing world. However, despite the promised benefits, the commercialization of plant-derived pharmaceutical products is overshadowed by the uncertain regulatory terrain, particularly with regard to the adaptation of good manufacturing practice regulations to field-grown plants. The success of such products also depends on careful negotiation of the intellectual property landscape, particularly the achievement of freedom-to-operate licenses for use in developing countries
A mechanism for morphogen-controlled domain growth
Many developmental systems are organised via the action of graded distributions of morphogens. In the Drosophila wing disc, for example, recent experimental evidence has shown that graded expression of the morphogen Dpp controls cell proliferation and hence disc growth. Our goal is to explore a simple model for regulation of wing growth via the Dpp gradient: we use a system of reaction-diffusion equations to model the dynamics of Dpp and its receptor Tkv, with advection arising as a result of the flow generated by cell proliferation. We analyse the model both numerically and analytically, showing that uniform domain growth across the disc produces an exponentially growing wing disc
Expression and regulation of neuron-specific enolase
SIGLEAvailable from British Library Document Supply Centre-DSC:DXN005871 / BLDSC - British Library Document Supply CentreGBUnited Kingdo
Control of Gene Expression, Regulation of Transcripion
The utility of any transgenic plant is ultimately dependent upon the robust control of transgene expression. In this chapter we examine how various endogenous systems that control gene expression in the host genome can lead to transgene silencing. We then explore approaches to mitigate these effects and particularly focus on the benefits offered by chloroplast transformation